Nine Masts Capital’s Pfizer PFE Stock Holding History

Nine Masts Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.64M	Buy	+68,200	New	+$1.78M	0.17%	51
2018 Q2	–	Sell	-6,008	Closed	-$202K	–	357
2018 Q1	$202K	Sell	6,008 -17,180	-74%	-$591K	0.03%	140
2017 Q4	$797K	Buy	+23,188	New	+$791K	0.11%	70
2017 Q3	–	Sell	-12,332	Closed	-$393K	–	247
2017 Q2	$393K	Buy	+12,332	New	+$389K	0.05%	91

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nine Masts Capital's PFE Position: Q2 2026 in Review

Nine Masts Capital opened a new position in Pfizer (PFE) in Q2 2026: 68,200 shares worth $1.64M. The stake represents 0.17% of the portfolio and ranks #51 among its holdings. This is a return to the name: Nine Masts Capital previously reported a position in PFE as recently as Q1 2018.

Nine Masts Capital first reported a position in PFE in Q2 2017 and has held it in 4 quarters since. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Nine Masts Capital held 68,200 shares of Pfizer worth $1.64M as of Q2 2026.
Pfizer was a new Nine Masts Capital position in Q2 2026.
Pfizer made up 0.17% of Nine Masts Capital's portfolio in Q2 2026, its #51 holding.
Nine Masts Capital first reported a position in Pfizer in Q2 2017 and has held it in 4 quarters since.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.